Organization (Academic)
Xinjiang Medical University
ClinicalTrials.gov lists Xinjiang Medical University as lead sponsor of 21 trials. It has 1 active development program and 11 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 6 registered with a 2026 start date. The dashed outline is the pace from the 6 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Xinjiang Medical University: 21 lead-sponsored trials and 1 legal-entity registration.
Disease areas (35)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Coronary Disease | 4 |
| Hyperaldosteronism | 4 |
| Breast Neoplasms | 3 |
| Heart Failure | 3 |
| Carcinoma, Non-Small-Cell Lung | 2 |
Showing 5 of 35 disease areas.
Trials by start year as sponsor or collaborator (14)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 3 |
| 2024 | 3 |
| 2023 | 3 |
| 2021 | 1 |
| 2020 | 2 |
| 2019 | 1 |
| 2017 | 1 |
| 2016 | 3 |
| 2015 | 2 |
Showing 10 of 14 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1)
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Drug:Standard therapy | Coronary Disease | Not reported | 1 |
Approved assets (11)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Erlotinib | 1 |
| DOCETAXEL | 1 |
| PEMETREXED | 1 |
| RITUXIMAB | 1 |
| Epirubicin | 1 |
Showing 5 of 11 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| not enough data | 1 of 1 on time (n=1) |
Journals published in (54)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 9 |
| Hepatology (Baltimore, Md.) | 5 |
| Reviews in cardiovascular medicine | 4 |
| Annals of oncology : official journal of the European Society for Medical Oncology | 3 |
| Circulation | 3 |
Showing 5 of 54 journals.
Organization relationships (6)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| First Hospital of China Medical University | Co sponsors trial with | 1 |
| Tang Du Hospital | Co sponsors trial with | 1 |
| Air Force Military Medical University, China | Co sponsors trial with | 1 |
| People's Hospital of Ningxia Hui Autonomous Region | Co sponsors trial with | 1 |
| Guanxian County People's Hospital | Co sponsors trial with | 1 |
Showing 5 of 6 relationships.
Latest dated events (33)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 33 events.
Biomarker capability evidence (20)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| NPPB | Trial sponsor | Named in trial inclusion criteria |
| REN | Trial sponsor | Named in trial inclusion criteria |
| SIT1 | Trial sponsor | Named in trial inclusion criteria |
| CD5 | Trial sponsor | Named in trial exclusion criteria |
| CYP3A4 | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 20 evidence rows.
Biomarkers this organization publishes on (43)
Shown in this order: most publications first.
Showing 5 of 43 biomarkers.
On Scientist.com
Xinjiang Medical University is listed as a research supplier in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.
Work with XinJiang Medical University (The First Affiliated Hospital) on Scientist.com
For prices, more details, or to contact XinJiang Medical University (The First Affiliated Hospital), visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.